JP2019528271A - ウイルスワクチン - Google Patents

ウイルスワクチン Download PDF

Info

Publication number
JP2019528271A
JP2019528271A JP2019508842A JP2019508842A JP2019528271A JP 2019528271 A JP2019528271 A JP 2019528271A JP 2019508842 A JP2019508842 A JP 2019508842A JP 2019508842 A JP2019508842 A JP 2019508842A JP 2019528271 A JP2019528271 A JP 2019528271A
Authority
JP
Japan
Prior art keywords
virus
smallpox
composition
infection
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019508842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528271A5 (enExample
Inventor
ハウリー、ポール
Original Assignee
セメンティス リミテッド
セメンティス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903295A external-priority patent/AU2016903295A0/en
Application filed by セメンティス リミテッド, セメンティス リミテッド filed Critical セメンティス リミテッド
Publication of JP2019528271A publication Critical patent/JP2019528271A/ja
Publication of JP2019528271A5 publication Critical patent/JP2019528271A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019508842A 2016-08-19 2017-08-18 ウイルスワクチン Pending JP2019528271A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016903295 2016-08-19
AU2016903295A AU2016903295A0 (en) 2016-08-19 Viral Vaccines
PCT/AU2017/050879 WO2018032057A1 (en) 2016-08-19 2017-08-18 Viral vaccines

Publications (2)

Publication Number Publication Date
JP2019528271A true JP2019528271A (ja) 2019-10-10
JP2019528271A5 JP2019528271A5 (enExample) 2020-05-14

Family

ID=61195904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019508842A Pending JP2019528271A (ja) 2016-08-19 2017-08-18 ウイルスワクチン

Country Status (18)

Country Link
US (2) US10905759B2 (enExample)
EP (2) EP3500280A4 (enExample)
JP (1) JP2019528271A (enExample)
KR (1) KR20190050787A (enExample)
CN (1) CN109862909A (enExample)
AR (1) AR110624A1 (enExample)
AU (1) AU2017313450B2 (enExample)
CA (2) CA3034282A1 (enExample)
CL (1) CL2019000405A1 (enExample)
IL (1) IL264893B (enExample)
MA (1) MA45994A (enExample)
MX (1) MX2019001919A (enExample)
MY (1) MY200887A (enExample)
NZ (1) NZ750578A (enExample)
SG (1) SG11201900814QA (enExample)
TW (1) TWI728173B (enExample)
WO (1) WO2018032057A1 (enExample)
ZA (1) ZA201900641B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023520080A (ja) * 2020-03-31 2023-05-15 セメンティス リミテッド Ｃｏｖｉｄ－１９に対する保護のための弱毒化されたポックスウイルスベクターをベースとするワクチン

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117378A1 (en) * 2018-10-22 2020-04-30 Icellkealex Therapeutics Llc Mutant vaccinia viruses and use thereof
CN112362877B (zh) * 2020-10-27 2024-04-12 江苏先声医学诊断有限公司 一种mbp重组蛋白以及其应用
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09512707A (ja) * 1994-04-29 1997-12-22 イムノ・アクテイエンゲゼルシヤフト 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス
JP2006506974A (ja) * 2002-08-12 2006-03-02 デイビッド キルン ポックスウイルスおよび癌に関する方法および組成物
JP2006517795A (ja) * 2003-02-18 2006-08-03 ゲーエスエフ フォーシュングスツェントラム フュール ウンヴェルト ウント ゲズントハイト ゲーエムベーハー 組換えｍｖａおよびその生産方法
WO2015061858A1 (en) * 2013-11-01 2015-05-07 Sementis Limited Viral vector manufacture
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418951A (zh) 2001-05-23 2003-05-21 广州绿健生物技术有限公司 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法
PL218318B1 (pl) * 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
KR20040015624A (ko) 2002-08-13 2004-02-19 대한뉴팜(주) 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물
EP1518932A1 (en) * 2003-09-29 2005-03-30 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Modified vaccinia virus Ankara (MVA) mutant and use thereof
EP1683870A1 (en) * 2005-01-24 2006-07-26 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Vaccines based on the use of MVA
GB201006405D0 (en) * 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
AU2011305348A1 (en) 2010-09-23 2013-04-18 Baxter Healthcare Sa Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
WO2014138824A1 (en) * 2013-03-15 2014-09-18 Sementis Limited Immune modulation
WO2017136419A1 (en) 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09512707A (ja) * 1994-04-29 1997-12-22 イムノ・アクテイエンゲゼルシヤフト 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス
JP2006506974A (ja) * 2002-08-12 2006-03-02 デイビッド キルン ポックスウイルスおよび癌に関する方法および組成物
JP2006517795A (ja) * 2003-02-18 2006-08-03 ゲーエスエフ フォーシュングスツェントラム フュール ウンヴェルト ウント ゲズントハイト ゲーエムベーハー 組換えｍｖａおよびその生産方法
WO2015061858A1 (en) * 2013-11-01 2015-05-07 Sementis Limited Viral vector manufacture
WO2016086980A1 (en) * 2014-12-02 2016-06-09 Consejo Superior De Investigaciones Cientificas Vaccine composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NATURE, (2016.06.28), 536, [7617], P.474-478, <DOI:10.1038/NATURE18952>, JPN6021019139, ISSN: 0004748135 *
PLOS ONE, (2014), 9, [9], ARTICLE.E108169, JPN6021019138, ISSN: 0004748133 *
天然痘(痘瘡), [ONLINE], (2014.09), MSDマニュアル プロフェッショナル版, [2021.05.17検索], インターネ, JPN6021019140, ISSN: 0004748134 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023520080A (ja) * 2020-03-31 2023-05-15 セメンティス リミテッド Ｃｏｖｉｄ－１９に対する保護のための弱毒化されたポックスウイルスベクターをベースとするワクチン
JP7544399B2 (ja) 2020-03-31 2024-09-03 セメンティス リミテッド Ｃｏｖｉｄ－１９に対する保護のための弱毒化されたポックスウイルスベクターをベースとするワクチン

Also Published As

Publication number Publication date
US20210113684A1 (en) 2021-04-22
EP3500280A4 (en) 2020-05-13
EP4331676A3 (en) 2024-05-15
MY200887A (en) 2024-01-22
IL264893A (enExample) 2019-04-30
BR112019003181A2 (pt) 2019-07-16
MX2019001919A (es) 2019-09-04
CL2019000405A1 (es) 2019-06-14
RU2019107582A3 (enExample) 2021-03-31
US20200009245A1 (en) 2020-01-09
AU2017313450B2 (en) 2024-02-15
AR110624A1 (es) 2019-04-17
TWI728173B (zh) 2021-05-21
SG11201900814QA (en) 2019-03-28
MA45994A (fr) 2021-03-17
EP4331676A2 (en) 2024-03-06
WO2018032057A1 (en) 2018-02-22
IL264893B (en) 2022-08-01
RU2019107582A (ru) 2020-09-21
EP3500280A1 (en) 2019-06-26
NZ750578A (en) 2023-05-26
CA3034282A1 (en) 2018-02-22
ZA201900641B (en) 2025-10-29
KR20190050787A (ko) 2019-05-13
TW201809273A (zh) 2018-03-16
AU2017313450A1 (en) 2019-02-28
US10905759B2 (en) 2021-02-02
CN109862909A (zh) 2019-06-07
CA3265584A1 (en) 2025-03-14

Similar Documents

Publication Publication Date Title
JP6818797B2 (ja) 強靭なｔ細胞用のｐｒ１３．５プロモータ及び抗体応答
JP7544399B2 (ja) Ｃｏｖｉｄ－１９に対する保護のための弱毒化されたポックスウイルスベクターをベースとするワクチン
JP3826055B2 (ja) 組換えアビポックスウイルスによる免疫方法
Paillot et al. Equine herpes virus-1: virus, immunity and vaccines
AU2003239805B2 (en) Modified vaccinia virus ankara for the vaccination of neonates
US20210113684A1 (en) Vector-based attenuated poxvirus vaccines
CN105980570A (zh) Cmv疫苗
JP2003503039A (ja) 弱毒化したワクチンの操作のための方法および組成物
WO2022071513A1 (ja) ＳＡＲＳ－ＣｏＶ－２に対する改良型ＤＮＡワクチン
JP2020039340A (ja) ウイルスベクターの作製
KR20230022206A (ko) 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신
JP2021518152A (ja) 標的タンパク質を安定して発現できる組換えウイルス
US20090304738A1 (en) Methods for Enhancing Immune Responses
WO2006002594A1 (en) A recombinant canine adenovirus type-2 and the preparation method and usage thereof
RU2778312C2 (ru) Вирусные вакцины
BR112019003181B1 (pt) Composição para aumentar uma resposta imune em animal, método para induzir uma resposta imune protetora em um sujeito, e, uso da composição na preparação de um medicamento
Joshi Development of Parapoxvirus ORFV Virus as a Vaccine Delivery Platform for Use in Swine
Skinner et al. Advances in fowlpox vaccination.
KR20200124713A (ko) 외인성 펠라인 파라믹소바이러스 유전자를 발현하는 재조합 바이러스 벡터 시스템 및 이로부터 제조된 백신
HIREMATH DEVELOPMENT OF SHEEP POX VIRUS VECTORED FOOT AND MOUTH DISEASE VACCINE FOR SHEEP

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190412

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20190412

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220412